Hikma is set to add strength to its portfolio with an acquisition that marks its expansion into Canada.. The company is acquiring the Canadian assets of Teligent for $45.75 million. The ...

Hikma is set to strengthen its injectables portfolio. The company has agreed to acquire Custopharm from Water Street Healthcare Partners. Custopharm, a U.S.-based generic sterile injectables ...

Generic drugmaker Hikma Pharmaceuticals USA Inc has sued Amarin Pharma Inc, accusing it of using illegal tactics to delay generic competition for its heart drug Vascepa. In a complaint filed ...

Hikma will benefit from 180 days of exclusivity in the U.S. generic market upon launch, the company added. More on Hikma Pharmaceuticals, Novartis, etc.

Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing ...

After Hikma initiated a recall of one batch of acetaminophen injection earlier this month, the company is extending the nationwide recall to the consumer level. The company started the recall (PDF ...

Hikma Pharmaceuticals (HKMPF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Hikma's branded generic will compete with Teva Pharmaceuticals (TEVA.TA), opens new tab authorized generic of Victoza in the United States that was launched earlier this year.

On July 22, Hikma Pharmaceuticals announced a voluntary recall of one lot of intravenous bags after a reported adverse event. Lot 24070381 is being pulled from the market because the bags might ...

Generic drugmaker Hikma Pharmaceuticals USA Inc has sued Amarin Pharma Inc, accusing it of using illegal tactics to delay generic competition for its heart drug Vascepa.